Macrogenics (MGNX) – Major News
-
Macrogenics (MGNX) Reports In-Line Q4 EPS
-
Macrogenics (MGNX) Tops Q3 EPS by 38c
-
Macrogenics (MGNX) Tops Q2 EPS, Revenues Miss
-
Macrogenics (MGNX) Misses Q1 EPS by 110c
-
Macrogenics (MGNX) Misses Q1 EPS by 22c
-
Macrogenics (MGNX) Misses Q2 EPS by 20c
-
Macrogenics (MGNX) Misses Q1 EPS by 29c, Revenues Miss
-
Macrogenics (MGNX) Tops Q3 EPS by 27c, Revenues Beat
-
Macrogenics (MGNX) Tops Q2 EPS by 8c, Revenues Beat
-
Macrogenics (MGNX) Tops Q1 EPS by 21c, Revenues Beat
-
Macrogenics (MGNX) Tops Q3 EPS by 7c
-
Macrogenics (MGNX) Reports FY18 Loss of $4.19/Share
-
Macrogenics (MGNX) Says FDA Removes Partial Clinical Hold on MGD009
-
Macrogenics (MGNX) Reports Partial Clinical Hold on MGD009 Phase 1 Studies
-
Macrogenics (MGNX) Tops Q2 EPS by 19c
-
Macrogenics (MGNX) Misses Q3 EPS by 19c
-
Macrogenics (MGNX) Misses Q1 EPS by 11c
-
Macrogenics (MGNX) Misses Q3 EPS by 17c
-
MacroGenics (MGNX) IPO Surges 50%
-
MacroGenics (MGNX) IPO Prices at $16, In-Line with Expectations
Back to MGNX Stock Lookup